Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Celldex to Present at Upcoming Investor Conferences
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study